EDEN PRAIRIE, MN, and REHOVOT, Israel, and EXTON, PA — Stratasys Ltd. (NASDAQ: SSYS) and Ricoh USA, Inc. have announced the enrollment of the first patient in a pioneering clinical study. This research will explore the efficacy of using 3D printed anatomical models for preoperative planning in orthopedic oncology, comparing it against the current reliance on CT or MRI imaging alone.
This joint effort between Stratasys, a leader in 3D printing technology, and Ricoh USA, Inc., aims to showcase the potential improvements that patient-specific 3D printed models can bring to surgical outcomes. The study hypothesizes that these tangible models could lead to reduced blood loss, shorter operating times—including time under anesthesia—and a decreased risk of procedural complications.
Unlike traditional imaging methods, 3D printed models offer a life-size physical replica of the patient’s anatomy, providing surgeons with a practical tool for simulating and practicing complex procedures before entering the operating room. This not only enhances the precision of tumor excisions but also significantly reduces the likelihood of patients needing additional surgeries due to positive margins.
The study is designed as a prospective, multi-center randomized controlled trial and will span 12 months, involving up to 150 subjects at three sites. Currently, The Ohio State University Wexner Medical Center and Corewell HealthTM in Michigan have committed to participate.
Dr. Kyle K. VanKoevering from the Ohio State Wexner Medical Center highlighted the importance of preoperative planning in improving patient outcomes, stating, “Our never-ending mission is to improve patient outcomes, and that starts with preoperative planning.” He expressed optimism about the study’s potential to enhance both surgical preparation and patient education through the use of 3D printed models.
Meanwhile, Dr. Aws Hammad of Corewell Health William Beaumont University Hospital noted the significance of being part of a study that pioneers new technologies to advance patient care.
Gary Turner, Managing Director of Additive Manufacturing at Ricoh USA, Inc., shared his excitement about the collaboration with Stratasys, emphasizing the trial’s role in demonstrating the impact of 3D patient-specific modeling. He stated, “We are thrilled to co-sponsor this important clinical trial…to further demonstrate the potential impact of 3D patient-specific modeling as well as accelerate adoption of this technology to better serve a broader population.”
With the backing of two leading institutions in the medical and technology fields, this study promises to provide invaluable insights into the benefits of integrating 3D printing technology into the realm of surgical planning and execution, potentially setting a new standard in the treatment of orthopedic oncology patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.